Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Mallinckrodt
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or nonpregnant, nonlactating female subjects
Meets criteria for definite rheumatoid arthritis as defined by 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification at screening
Has active disease defined as a score of \>3.2 on DAS28-ESR prior to study drug administration despite dual-DMARD treatment
Is on a stable dose of ≤ 20 mg per week of methotrexate for at least 8 weeks AND a stable dose of an allowed DMARD for at least 24 weeks prior to the screening visit
May also be on a stable dose of 10 mg or less of prednisone or other the dose equivalent of another corticosteroid for 4 weeks prior to study drug administration
You may not be if
Has current rheumatoid disease or inflammatory joint disease other than RA
Has any history of use of adrenocorticotropic hormone (ACTH) for the treatment of RA
Has taken B-cell mediated therapies in the 6 months prior to screening
Has hepatitis B, hepatitis C, history of tuberculosis (TB) or other contraindication as per the United States (US) Prescribing Information for Acthar
Has history of Type 1 or Type 2 diabetes
Has any clinically significant infection
Clareo Health | Safety and Effectiveness of Acthar Gel in Participants With Rheumatoid Arthritis
